Comparative efficacy and safety of the trastuzumab biosimilar HLX02 versus originator trastuzumab in the neoadjuvant THP-EC regimen for early-stage HER2-positive breast cancer: a real-world study
{{output}}
Objectives: HER2-positive breast cancer is an aggressive subtype. High-cost originator trastuzumab limits treatment access, making biosimilars like HLX02 a valuable alternative. ... ...
